PerkinElmer Offering $500M in Senior Notes to Fund Caliper Purchase | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – PerkinElmer today announced the pricing of a $500 million offering to be used in part to fund its $600 million purchase of Caliper Life Sciences.

The senior notes carry an aggregate principal amount of 5 percent and are due 2021 at an issue price of 99.372 percent of the principal amount. The issuance of the notes is expected to close Oct. 25. The notes will pay interest on a semi-annual basis.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.